PPARG and metabolic dysfunction-associated steatohepatitis: PPARγ agonist pioglitazone showed an improvement of NASH endpoints (steatosis, inflammation, and ballooning hepatocytes) but did not significantly improve fibrosis regression in patients with impaired glucose tolerance/type 2 diabetes (45 mg/day, n = 26) or non-diabetic patients with NASH (30 mg/day, n = 70) compared to placebo controls (n = 21 and n = 72, respectively) [151,152].